Pfizer announced Thursday plans to move forward with an oral daily weight loss medication in the same drug category as treatments including Ozempic and Zepbound. The pharmaceutical giant said clinical evaluation of once-daily doses its oral GLP-1 agonist candidate danuglipron demonstrated "encouraging" data. Dose optimization studies are planned. Pfizer had been looking into a twice-daily version of danuglipron last year but decided against advancing the iteration due to side effects among trial participants such as nausea and vomiting. “Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates. The m
Hence then, the article about pfizer moving ahead with plans for once daily weight loss pill was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Pfizer moving ahead with plans for once-daily weight loss pill )